Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Altimmune Inc. | Pemvidutide - (MOMENTUM) | Non-alcoholic steatohepatitis (NASH)/ (MASH) - Healthy, Overweight and Obese Volunteers | Phase 2 | Data Released | Subcutaneous | Gastroenterology |
| Altimmune Inc. | Pemvidutide - (RESTORE) | Alcohol-Associated Liver Disease (ALD) | Phase 2 | Enrollment Initiation | Subcutaneous | Gastroenterology |
| Altimmune Inc. | Pemvidutide - (IMPACT) | Metabolic dysfunction-associated steatohepatitis (MASH) | Phase 3 | Trial Planned | Subcutaneous | Gastroenterology |
| Altimmune Inc. | HepTCell | Hepatitis B | Phase 2 | Trial Discontinued | Intramuscular | Antiviral |
| Altimmune Inc. | HepTCell | Hepatitis B | Phase 2 | Trial Discontinued | Intramuscular | Antiviral |
| Altimmune Inc. | Pemvidutide | Alcohol Liver Disease (ALD) | Phase 2 | Trial Planned | Subcutaneous | Gastroenterology |
| Altimmune Inc. | Pemvidutide - (RECLAIM) | Alcohol Use Disorder (AUD) | Phase 2 | Ongoing | Subcutaneous | Psychiatric |
| Alto Neuroscience Inc. | ALTO-207 (CTC-501) - (PAX-D) | Treatment-resistant depression (TRD) | Phase 2b | Ongoing | Oral | Psychiatric |
